**National Center for Emerging and Zoonotic Infectious Diseases** 



### **Considerations for long-term protection against mpox**

Agam Rao, MD CAPT, US Public Health Service Medical Officer Poxvirus and Rabies Branch

#### **Advisory Committee on Immunization Practices** June 23, 2023

## **CDC collaborative studies examining serologic response to JYNNEOS vaccinations**

Study	Goals	Timepoints/Duration	Participant Information
<ul> <li><u>DRC</u></li> <li>Healthcare personnel</li> <li>Democratic Republic of the Congo, Tshuapa Province</li> </ul>	<ul> <li>Safety</li> <li>Immunogenicity</li> <li>Effectiveness</li> </ul>	<ul> <li>2-year studies</li> <li>Serum obtained on days 0, 14, 28, and 42, and 6, 12, 18, 24 months</li> <li>Booster: 5 years</li> <li>Serum obtained on days 0, 7, 14</li> </ul>	<ul> <li>1000 participants SC/SC liquid formulation</li> <li>600 participants SC/SC lyophilized formulation</li> <li>~170 participants (Booster)</li> </ul>
<ul> <li><u>DC PEP++</u></li> <li>Expanded post-exposure prophylaxis in MSM with behaviors that increase risk for mpox</li> <li>DC Health</li> <li>Washington, DC</li> </ul>	<ul> <li>Immunogenicity</li> <li>Comparison between different routes of vaccination</li> </ul>	<ul> <li>2-year study</li> <li>Days 0, 28, and 42-56 and 6 months</li> <li>12, 18, and 24 months planned.</li> </ul>	<ul> <li>330 participants</li> <li>Participants with 2 timepoints (n=216), 3 timepoints (n=70), or all 4 timepoints (n=66)</li> </ul>

## **CDC studies examining serologic response to JYNNEOS vaccinations**

Study	Goals	Timepoints/Duration	Participant Information
<ul> <li><u>DRC</u></li> <li>Healthcare personnel Democratic Republic of the Congo, Tshuapa Province</li> </ul>	<ul> <li>Safety</li> <li>Immunogenicity</li> <li>Effectiveness</li> </ul>	<ul> <li>2-year studies</li> <li>Serum obtained on days 0, 14, 28, and 42, and 6, 12, 18, 24 months</li> <li>Booster dose: 5 years</li> <li>Serum obtained on days 0, 7, 14</li> </ul>	<ul> <li>1000 participants SC/SC liquid formulation</li> <li>600 participants SC/SC lyophilized formulation</li> <li>~170 participants (Booster)</li> </ul>
<ul> <li><u>DC PEP++</u></li> <li>Expanded post-exposure prophylaxis in MSM with behaviors that increase risk for mpox</li> <li>DC Health</li> <li>Washington, DC</li> </ul>	<ul> <li>Immunogenicity</li> <li>Comparison between different routes of vaccination</li> </ul>	<ul> <li>2-year study</li> <li>Days 0, 28, and 42-56 and 6 months</li> <li>12, 18, and 24 months planned.</li> </ul>	<ul> <li>330 participants</li> <li>Participants with 2 timepoints (n=216), 3 timepoints (n=70), or all 4 timepoints (n=66)</li> </ul>

## **CDC studies examining serologic response to JYNNEOS vaccinations**


Study	Goals	Timepoints/Duration	Participant Information
<ul> <li><u>DRC</u></li> <li>Healthcare personnel Democratic Republic of the Congo, Tshuapa Province</li> </ul>	<ul> <li>Safety</li> <li>Immunogenicity</li> <li>Effectiveness</li> </ul>	<ul> <li>2-year studies</li> <li>Serum obtained on days 0, 14, 28, and 42, and 6, 12, 18, 24 months</li> <li>Booster dose: 5 years</li> <li>Serum obtained on days 0, 7, 14</li> </ul>	<ul> <li>1000 participants SC/SC liquid formulation</li> <li>600 participants SC/SC lyophilized formulation</li> <li>~170 participants (Booster)</li> </ul>
<ul> <li><u>DC PEP++</u></li> <li>Expanded post-exposure prophylaxis in MSM with behaviors that increase risk for mpox</li> <li>DC Health</li> <li>Washington, DC</li> </ul>	<ul> <li>Immunogenicity</li> <li>Comparison between different routes of vaccination</li> </ul>	<ul> <li>2-year study</li> <li>Days 0, 28, and 42-56 and 6 months</li> <li>12, 18, and 24 months planned.</li> </ul>	<ul> <li>330 participants</li> <li>Participants with 2 timepoints (n=216), 3 timepoints (n=70), or all 4 timepoints (n=66)</li> </ul>

## **CDC studies examining serologic response to JYNNEOS vaccinations**

Study	Goals	Timepoints/Duration	Participant Information
<ul> <li><u>DRC</u></li> <li>Healthcare personnel Democratic Republic of the Congo, Tshuapa Province</li> </ul>	<ul> <li>Safety</li> <li>Immunogenicity</li> <li>Effectiveness</li> </ul>	<ul> <li>2-year studies</li> <li>Serum obtained on days 0, 14, 28, and 42, and 6, 12, 18, 24 months</li> <li>Booster dose: 5 years</li> <li>Serum obtained on days 0,</li> </ul>	<ul> <li>1000 participants SC/SC liquid formulation</li> <li>600 participants SC/SC lyophilized formulation</li> <li>~170 participants (Booster)</li> </ul>
<ul> <li><u>DC PEP++</u></li> <li>Expanded post-exposure prophylaxis in MSM with behaviors that increase risk for mpox</li> <li>DC Health</li> <li>Washington, DC</li> </ul>	<ul> <li>Immunogenicity</li> <li>Comparison between different routes of vaccination</li> </ul>	<ul> <li>7, 14</li> <li>2-year study</li> <li>Days 0, 28, and 42-56 and 6 months</li> <li>12, 18, and 24 months planned.</li> </ul>	<ul> <li>330 participants</li> <li>Participants with 2 timepoints (n=216), 3 timepoints (n=70), or all 4 timepoints (n=66)</li> </ul>

## DRC study: Detection of IgG antibody after JYNNEOS vaccination

- Serum specimens tested for presence of orthopoxvirus-specific
   IgG antibody using an enzymelinked immunosorbent assay (ELISA)
- Positivity determined by Optical
   Density (OD) cutoff value (COV)
- Circulating IgG levels peaked slower and lower in persons who received no previous orthopoxvirus vaccine
- Circulating IgG levels stayed higher for a longer period of time in persons previously vaccinated



Days from JYNNEOS dose 1

\*Prior vaccination was not with JYNNEOS; it was a vaccine to prevent smallpox that was received during childhood

## **2022 ACIP recommendations for persons at occupational risk for orthopoxvirus exposures**

- Reviewed data indicated an anamnestic response occurs 2 years after the 2-dose series
- ACIP recommendations: persons (typically laboratorians) at occupational risk for variola virus and MPXV exposures should receive JYNNEOS booster doses every 2 years
- No data to indicate whether anamnestic response would occur >2 years after 2-dose series; standard-of-care for these persons working with research grade virus has been booster doses

### **WG's interpretation**

 Significance of waning circulating antibody levels is unknown
 Anamnestic response elicited 2 years after JYNNEOS primary series
 2022 ACIP recommendations were for exposures that are different from those experienced during the current outbreak

## Real-world data during 2022/2023 U.S. mpox outbreak

- VE studies
  - 3 studies: NY State, Epic Cosmos, and Multijurisdictional Case-Control Studies
  - VE ranged from 36%–75% for 1 dose and 66%–89% for 2 doses
- Mpox cases among persons who received 2 doses have occurred: Some cases expected; reported as early as August 2022
- 2023 Chicago cluster involving persons who received 2 JYNNEOS doses\*
  - No U.S. clusters of a similar size reported
  - No hospitalizations; opiates not typically prescribed for pain control
  - Sequences typical of B.1 variant of MPXV Clade IIb; no mutations that would confer increased pathogenicity

### WG's interpretation

#### Third dose currently not indicated for entire population eligible for vaccination

## Additional vaccine doses for immunocompromised persons, including persons with HIV

## Safety of third dose of JYNNEOS


#### **Current Knowledge**

CDC's DRC study: Study of HCP shows increased adverse events among recipients of 3<sup>rd</sup> dose at 5 years after primary series

#### **Limitation**

 Study population may not be representative of U.S. population

Select vaccine-associated adverse events, by dose, healthcare personnel in Democratic Republic of Congo (n=706 for first and second doses and n=170 for 3<sup>rd</sup>



Minhaj et al, unpublished data, 2023

## Safety of third dose of JYNNEOS in persons with HIV


#### **Current Knowledge**

Study of persons with HIV (CD4 100– 500) shows increased adverse events (albeit not significant) among recipients of third dose at week 12

#### **Limitation**

Small numbers of total subjects; only 30 patients received third dose; difficult to know likelihood of increased adverse events

Select vaccine-associated adverse events, by dose, among persons with HIV in the United States (n=87 for 1<sup>st</sup> and 2<sup>nd</sup> doses, n= 30 for third dose)



### **WG's interpretation**

#### Third dose might result in more adverse events; this could deter some persons from receiving first and second doses


## Serologic Response to JYNNEOS among persons with HIV

#### **Current Knowledge**

 For nearly 600 persons with CD4 >200\*, serologic response to 2-dose series equivalent to response in persons without HIV

#### **Limitation**

 No assessment of serologic response for persons with CD4 <100</li>



\* measured in cells/mm<sup>3</sup>


Greenberg 2013 J Infect Dis; Overton 2015 Open Forum Infect Dis;

## Serologic Response to JYNNEOS among persons with HIV <u>Current Knowledge</u>

- For persons with CD4 100-500\* and lifetime nadir <200\*, serologic response of 3 doses is similar to 2 doses
- Review of unpublished data: No correlation between low CD4 count and antibodies after vaccine

\* measured in cells/mm<sup>3</sup>

- Serologic correlate of protective immunity unknown
- Small number of subjects: only 26 subjects in 3-dose arm



# VE of JYNNEOS in persons with self-reported immunocompromise (including HIV)


#### **Current Knowledge**

VE point estimates for persons who are immunocompromised\* lower than for general population of vaccinated persons for both 1 and 2 doses

\* predominately HIV (CD4 cell count not specified)

#### **Limitation**

- Estimates do not differ statistically from estimates for general population
- Few persons for whom this was evaluated; Confidence Intervals wide



# Severity of infections among fully vaccinated: National reporting and anecdotal reports

#### **Current Knowledge**

- >10,000 mpox cases among persons with HIV; however no confirmed reports of severe mpox illness after full vaccination
- CDC reviewed data reported from health departments for fully vaccinated persons with mpox and confirmed none were hospitalized due to severe manifestations of mpox
- Anecdotally, CDC told there was a severe case in a patient who was not fully vaccinated; however, details not known


#### **Limitation**

- Data extrapolated from surveillance and consultation data; no formal review of electronic health records linked to vaccine registries
- Not known whether persons who do not respond to 2 doses of JYNNEOS would respond to a third dose

### **WG's interpretation**

There is no convincing data to indicate patients with moderate-severe immunocompromise would benefit from an additional dose of JYNNEOS

## First and Second Doses of JYNNEOS Vaccine Administrations–United States, May, 2022 to May 2023



### **Conclusions**

- WG prefers no CDC recommendation for third JYNNEOS dose at this time, including for persons with advanced HIV or other severe immunocompromise
- WG emphasized several strategies
  - Encourage 2-dose vaccinations among persons who do not have immunity\*
  - Prevent or minimize life-threatening manifestations
    - Optimizing immune function (e.g., with HIV antiretrovirals), ideally before mpox exposure
    - Using CDC interim treatment considerations<sup>§</sup> to manage patients with (or at risk of) severe manifestations of mpox

\*e.g., persons who have not had mpox § Rao et al. 2023. MMWR

### Next steps

- Continue to collect and evaluate any existing data, particularly about use of JYNNEOS in immunocompromised persons
- Attempt to characterize severity of mpox cases experienced by people who received 2 JYNNEOS doses
- Continue ongoing VE studies
- Update CDC interim clinical considerations\* if additional JYNNEOS vaccine doses are recommended

## Acknowledgements

- ACIP mpox WG
- John Brooks
- Rosalind Carter
- Chris Braden
- Christy Hutson
- Sathesh Panayampalli
- Michael Townsend
- Shireesha Dhanireddy
- Inger Damon
- Faisal Minhaj

- Erin Whitehouse
- Allie Tuttle
- Sarah Guagliardo
- William Bower
- Andrea McCollum
- Emily Faherty
- Willie Bower
- Christy Hughes
- Bavarian Nordic

### **Questions and Comments?**

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

